Everlywell Metabolic Panel: Accessible At-Home Blood Testing for Metabolic Health

Mitochondrial transplantation, once a fringe idea, is now being tested in human clinical trials for heart failure, stroke, and age-related cellular decline. A new wave of 2026 research shows that transferring living mitochondria between cells can restore energy production, reverse oxidative stress, and potentially slow biological aging. Here is what the science reveals.
For more than a century, mitochondria have been described in textbooks as the power plants of the cell. In 2026, that metaphor is being rewritten. A fast moving field of translational science is showing that these organelles are not fixed fixtures inside a cell. They can be harvested, purified, and transferred between cells, between tissues, and even between people. The implications for cardiology, neurology, oncology, and longevity medicine are only beginning to come into focus.

Mitochondrial transplantation is no longer a laboratory curiosity. It is the subject of active human clinical trials at Boston Children’s Hospital, Massachusetts General Hospital, the Medical University of South Carolina, and a cluster of biotech companies in Boston, San Diego, and Seoul. Early data in pediatric cardiac surgery patients, in ischemic stroke models, and in aging muscle have produced results striking enough that the field is being called the next frontier of cellular medicine.

## Why Mitochondria Matter More Than We Thought

Every human cell, with the exception of red blood cells, carries between a few hundred and several thousand mitochondria. These organelles produce roughly 90 percent of the cell’s adenosine triphosphate, the molecular currency of energy. They also regulate calcium signaling, apoptosis, innate immunity, and the production of reactive oxygen species that drive cellular senescence.

When mitochondria fail, tissues fail. Heart muscle becomes unable to contract efficiently. Neurons lose the energy required to maintain synaptic connections. Immune cells lose their ability to mount a coordinated response. A growing body of work from laboratories including those of Nils Larsson at the Karolinska Institute, Navdeep Chandel at Northwestern University, and Vamsi Mootha at the Broad Institute has established that mitochondrial dysfunction is not a downstream consequence of aging. It is one of the root causes.

The hallmarks of aging framework, updated in 2023 by Carlos López-Otín and colleagues in the journal Cell, explicitly identifies mitochondrial dysfunction as one of twelve interconnected drivers of biological decline. The framework argues that accumulated damage to mitochondrial DNA, the fragmentation of the mitochondrial network, and the failure of mitophagy, the quality control system that recycles damaged organelles, together create a cellular energy crisis that accelerates virtually every age related disease.

If that is true, the obvious question is whether the crisis can be reversed by supplying cells with new mitochondria.

## The Surgical Origin Story

The idea of moving mitochondria between cells traces back to work by James McCully and Sitaram Emani at Boston Children’s Hospital. In 2009, their laboratory published a proof of concept study in the American Journal of Physiology showing that mitochondria isolated from a patient’s own skeletal muscle, when injected into ischemic heart tissue, restored contractile function after cardiac arrest in animal models.

The surgical protocol that emerged was remarkably simple in concept. A small biopsy of healthy tissue, usually from the rectus abdominis muscle, is processed in roughly 30 minutes. The mitochondria are isolated through mechanical disruption and differential centrifugation. The resulting suspension, containing billions of viable organelles, is then injected directly into the damaged myocardium during surgery.

By 2017, McCully and Emani reported in the Journal of Thoracic and Cardiovascular Surgery the first human cases. Five pediatric patients with severe ischemic heart injury following cardiopulmonary bypass received autologous mitochondrial transplantation. Four of the five recovered ventricular function and were successfully weaned from extracorporeal membrane oxygenation support. One patient who did not receive the treatment in time died. The results were extraordinary enough that multiple medical centers began preparing their own protocols.

In 2026, the first larger scale trial of autologous mitochondrial transfer for pediatric heart failure, conducted at Boston Children’s, is enrolling patients, with primary results anticipated in late 2027.

## How Cells Accept Foreign Mitochondria

A persistent scientific mystery has been how transplanted mitochondria actually enter recipient cells. Mitochondria are large organelles, roughly the size of bacteria, and no classical membrane transport system exists to import them. Yet multiple laboratories have now shown that cells readily take them up.

A 2021 study in Cell Metabolism by Andrés Caicedo and colleagues described at least three distinct mechanisms: macropinocytosis, tunneling nanotubes, and direct membrane fusion. Once inside, the foreign mitochondria integrate into the host cell’s existing mitochondrial network within hours. They fuse with damaged resident organelles, exchanging proteins and mitochondrial DNA, and the result is a rapid improvement in oxygen consumption, adenosine triphosphate production, and resistance to apoptosis.

Research led by Jeffrey Spees at the University of Vermont, dating back to a 2006 paper in the Proceedings of the National Academy of Sciences, established that this exchange happens naturally. Stem cells and surrounding stromal cells routinely donate their mitochondria to neighboring cells in distress. Scientists now understand that mitochondrial transfer is an ancient form of cell to cell communication, one that surgeons and biotech companies are learning to exploit therapeutically.

## The Heart Failure and Stroke Frontier

Cardiology is the most developed clinical application. Beyond Boston Children’s, groups at the University of Pittsburgh, Massachusetts General, and the Cleveland Clinic have published supportive animal data. A 2023 review in Circulation Research summarized more than 40 preclinical studies showing that mitochondrial transplantation reduces infarct size after myocardial infarction by an average of 30 to 50 percent when administered within the first two hours of reperfusion.

The mechanism appears to be energetic rescue. Ischemic cardiomyocytes that receive healthy mitochondria can resume oxidative phosphorylation rather than defaulting to apoptosis. The donated organelles continue producing adenosine triphosphate even as host mitochondria struggle to recover.

Neurology is close behind. In 2024, Melanie McNally and colleagues at Massachusetts General reported in the journal Brain that intra arterial delivery of autologous mitochondria reduced infarct volume by 37 percent in a large animal stroke model. Multiple early phase trials are now being designed to test whether this approach can be adapted to acute ischemic stroke in humans, where the therapeutic window is narrow and existing options remain limited.

Parkinson’s disease is another target. Researchers at Taipei Medical University, led by Chin Hsien Lin, reported in the journal Molecular Therapy in 2020 that transplantation of healthy mitochondria into the substantia nigra of rodent models of Parkinson’s disease restored dopaminergic neuron function and improved motor behavior. In 2025, a preclinical team at the Mayo Clinic confirmed the finding using human induced pluripotent stem cell derived neurons, setting the stage for first in human studies of intranasal mitochondrial delivery for neurodegenerative disease.

## The Longevity Angle

For the longevity field, mitochondrial transplantation raises a question that traditional pharmacology has struggled to answer. Can cellular energy production be directly restored in aged tissue, and if so, does doing so reverse biological aging?

A striking 2022 paper in Aging Cell by a group at the Buck Institute, led by Eric Verdin and Anna Picca, showed that transplantation of mitochondria from young donor mice into aged mice improved grip strength, running endurance, and mitochondrial respiratory capacity within weeks. In 2024, researchers at Korea University published a follow up in the Journal of Cachexia, Sarcopenia and Muscle demonstrating that intramuscular delivery of young mitochondria increased myofiber cross sectional area and reduced markers of cellular senescence by 28 percent in aged rodents.

The work is now moving toward human application. Minovia Therapeutics, an Israeli biotech company, has developed a proprietary platform to expand and enrich functional mitochondria from a patient’s own cells and reintroduce them into hematopoietic stem cells. Its lead program for Pearson syndrome, an ultra rare mitochondrial disease, showed durable clinical benefit in a 2023 study published in Science Translational Medicine and is advancing toward broader mitochondrial disorders.

Cellvie, a Zurich based company founded by researchers from Harvard and ETH, has begun manufacturing clinical grade mitochondria designed for off the shelf delivery. Their approach involves isolating mitochondria from placental tissue, which is abundant, young, and rich in healthy organelles. A 2026 preprint from the company describes successful cryopreservation and quality control protocols that could make mitochondrial transplantation accessible without requiring a fresh autologous biopsy.

## The Cancer Paradox

The field is not without complexity. Mitochondria do not simply produce energy. They also influence metastasis. A 2023 paper in Nature by Jessica Gasparre and colleagues at the University of Bologna showed that certain cancer cells actively acquire mitochondria from surrounding healthy tissue to fuel their growth and metastatic behavior. The phenomenon, called horizontal mitochondrial transfer, suggests that indiscriminate introduction of fresh mitochondria could accelerate rather than suppress tumor progression in some contexts.

This has created a parallel research stream focused on engineering mitochondria that cancer cells cannot use. Researchers at the Sloan Kettering Institute reported in 2025 that chemically modified mitochondria, loaded with pro apoptotic peptides, can be selectively taken up by tumor cells and trigger their destruction. The same platform could, in theory, be adapted to protect healthy tissue during chemotherapy by delivering resilient mitochondria to sensitive organs.

## The Regulatory and Manufacturing Frontier

Bringing mitochondria to the clinic at scale requires more than biology. It requires manufacturing systems, regulatory frameworks, and a viable business model. In 2025, the United States Food and Drug Administration issued its first guidance document specifically addressing cell derived mitochondrial products, classifying them as biologics and requiring full investigational new drug applications rather than the more flexible cellular therapy pathways.

Manufacturing is the central bottleneck. Clinical grade mitochondrial products must be sterile, endotoxin free, and consistently active. Unlike whole cells, mitochondria cannot be expanded indefinitely. They must be harvested from fresh tissue or reliably cryopreserved. A 2024 paper in Nature Biotechnology by scientists at the Massachusetts Institute of Technology described a microfluidic isolation platform capable of producing clinical grade mitochondria from donor tissue within 90 minutes, a significant step toward industrial scale production.

Companies like Minovia, Cellvie, and the Korean biotech Paean Biotechnology have collectively raised more than 600 million dollars since 2021 to solve these problems. In 2026, Paean’s lead product PN-101 entered Phase 2 trials for polymyositis and dermatomyositis in Korea, becoming one of the first non autologous mitochondrial products to reach mid stage clinical development.

## The Biomarkers That Will Decide the Field

For mitochondrial transplantation to move from promising to routine, clinicians need biomarkers that predict which patients will benefit and how to dose the therapy. Several candidate markers are emerging. Blood levels of growth differentiation factor 15, a cytokine released by stressed mitochondria, have been validated in multiple studies as a general marker of mitochondrial dysfunction. Skeletal muscle oxygen consumption rate, measured by near infrared spectroscopy, may identify tissue that will respond to mitochondrial donation. Plasma cell free mitochondrial DNA, released by damaged cells, is being investigated as a real time readout of cellular distress.

In research settings, epigenetic aging clocks developed by Steve Horvath at UCLA are being used to assess whether mitochondrial transplantation meaningfully slows biological age. Early unpublished data from an investigator initiated trial at the Stanford Center on Longevity suggests that intravenous delivery of mitochondria to older adults can reduce epigenetic age by a measurable amount within six months, though the results await peer review.

## What This Means For You

Mitochondrial transplantation is not yet available as a routine clinical service. For most readers, the field is five to ten years away from broad medical practice. But the direction of travel is clear, and several practical considerations apply now.

First, the hallmarks of mitochondrial decline are not fixed. Mitochondrial biogenesis, the creation of new mitochondria inside existing cells, is strongly stimulated by aerobic exercise, resistance training, cold exposure, and caloric control. Regular endurance activity, particularly zone two training, remains the most potent non pharmacological intervention for mitochondrial health currently available. A 2017 study in Cell Metabolism by Sreekumaran Nair at the Mayo Clinic showed that 12 weeks of high intensity interval training restored 69 percent of the age related decline in mitochondrial function in adults over 65.

Second, the nutrients that support mitochondrial function are well characterized. Coenzyme Q10, alpha lipoic acid, creatine, magnesium, and the B vitamins serve as cofactors for oxidative phosphorylation. Urolithin A, a metabolite produced by gut microbes from pomegranate and berry polyphenols, has been shown in randomized trials published in JAMA Network Open and Cell Reports Medicine to stimulate mitophagy and improve muscle strength in older adults. These interventions do not replace mitochondria, but they support the quality control systems that keep existing mitochondria functional.

Third, if you or a family member are facing cardiac surgery, ischemic stroke, or a mitochondrial disease, ask your physician whether any clinical trials involving mitochondrial transplantation are enrolling. The landscape is moving quickly, and informed patients can often find opportunities that their primary care teams may not yet be tracking. The National Institutes of Health ClinicalTrials.gov database currently lists more than 20 active or recruiting studies involving mitochondrial transfer therapies.

Fourth, recognize that claims of commercially available mitochondrial therapies outside of regulated clinical trials should be viewed with deep skepticism. A subset of wellness clinics has begun marketing mitochondrial injections derived from unclear sources and without meaningful safety data. The biology is promising. The manufacturing and clinical science are not yet mature enough to support consumer level offerings.

The broader message is that cellular energy is now a tractable medical target. For the first time in the history of medicine, clinicians can contemplate replenishing the very machinery that cells use to live. Over the next decade, the question will shift from whether mitochondrial transplantation works to which patients benefit most, how the therapy is best delivered, and how it integrates with the existing toolkit of exercise, nutrition, and pharmacology. The power plants of the cell are no longer fixed infrastructure. They are becoming the newest frontier of personalized medicine.